09-25.06

Express Mail Label No.: EV 869858546 US Date of Deposit: September 22, 2006

Attorney Docket No.: 24024-506 CON



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

Peled, et al.

SERIAL NUMBER:

10/767,064

Anoop Kumar Singh

FILING DATE:

January 29, 2004

ART UNIT:

EXAMINER:

1632

For:

EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL

POPULATIONS IN MONONUCLEAR CELL CULTURES

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

- 1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
- 2. Modified Form 1449/PTO (12 pages), in duplicate;
- 3. Copies of Cited References: B8-24; C100-273; and
- 4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 24024-506 CON. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted

Ivor R. Elrifi, Reg. No. 39,529 Attorney(s) for Applicants MINTZ, LEVIN, COHN, FERRIS,

GLOVSKY and POPEO, P.C.

Address all written correspondence to

all. 59572

Customer no.: 30623 Tel: (617) 542-6000

Fax: (617) 542-2241

Date: September 22, 2006

Express Mail Label No.: EV 869858546 US Attorney Docket No.: 24024-506 CON

Date of Deposit: September 22, 2006

21 THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT Pelec

Peled, et al.

SERVAL NUMBER:

10/767,064

EXAMINER:

Anoop Kumar Singh

FILING DATE:

January 29, 2004

ART UNIT:

1632

For:

EX-VIVO EXPANSION OF HEMATOPOIETIC STEM CELL

POPULATIONS IN MONONUCLEAR CELL CULTURES

MAIL STOP AMENDMENT

Commissioner for Patents PO Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A9-A140 and the U.S. Published Applications A141-A148 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANT:

Peled, et al.

U.S.S.N.:

10/767,064

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 24024-506 CON.

Respectfully submitt

Ivor R. Elrifi, Reg. No. 39,529 Attorney(s) for Applicants

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY and POPEO, P.C.

Address all written correspondence to


BAL 50,572

Customer no.: 30623 Tel: (617) 542-6000

Fax: (617) 542-2241

Date: September 22, 2005

TRA 2201721v.1



Page 1 of 12 Attorney Docket No.: 24024-506 CON

Please type a plus sign (+) in this box

PTO/SB (12-97)

Approved for use through 9/30/00. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified	Form 1449/P1	го	- "		Application Number	10/767,	064			
					Filing Date	January	/ 29, 2004	ļ <u>, , , , , , , , , , , , , , , , , , ,</u>		
	INFOR	MATION DISC	LOSURE		First Named Inventor	Peled				
	STATE	MENT BY APP	PLICANT		Group Art Unit	1632				
					Examiner Name	Anoop I	Kumar Sir	ngh		
	(use as	s many sheets as ne	ecessary)		Attorney Docket Number	24024-5	506 CON			
				U.S.	PATENT DOCUMENTS	•				
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Nai	me of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate		
-	*A9	3,687,808	08-29-1972		Merigan Jr. et al.					
	*A10	4,036,945	07-10-1977		Haber		1			
	*A11	4,331,647	05-25-1982		Goldenberg		<u> </u>			
	*A12	4,469,863	04-04-1989		Ts'o et al.					
	*A13	4,476,301	09-09-1984		Imbach et al.					
	*A14	4,687,808	08-18-1987		Jarrett et al.		<u> </u>			
	*A15	4,816,567	03-28-1989		Cabilly et al.					
	*A16	4,866,052	09-12-1989		Hider et al.					
	*A17	4,868,116	09-19-1989		Morgan et al.		1			
	*A18	4,946,778	07-07-1990		Ladner et al.		-			
	*A19	4,980,286	12-25-1990	ļ <u>-</u>	Morgan et al.					
	*A20	5,013,830	07-07-1991	1	Ohtsuka et al.					
	*A21	5,023,243	06-11-1991		Tullis					
	*A22	5,034,506	07-23-1991		Summerton et al.					
	*A23	5,149,797	09-22-1992	ļ	Pederson et al.					
	*A24	5,166,315	11-24-1992		Summerton et al.		<u> </u>			
	*A25	5,166,320	11-24-1992		Wu et al.					
	*A26	5,177,196	05-05-1993	-	Meyer Jr. et al.		<u> </u>			
	*A27	5,185,444	09-09-1993		Summerton et al.		 			
	*A28	5,188,897	02-23-1993		Suhadolnik et al.		 			
	*A29	5,214,134	05-25-1993		Weis et al.		T			
	*A30	5,216,141	01-01-1993		Benner		<u> </u>			
	*A31	5,220,007	06-15-1993		Pederson et al.					
	*A32	5,235,033	08-10-1993		Summerton et al.					
	*A33	5,256,775	10-26-1993		Froehler					

Express Mail No.: EV 869858546 US Date of Deposit: September 22, 2006 Page 2 of 12 Attorney Docket No.: 24024-506 CON

	*A34	5,264,423	11-23-1993	Cohen et al.		
	*A35	5,264,562	11-23-1993	Matteucci		
	*A36	5,264,564	11-23-1993	Matteucci		
	*A37	5,276,019	04-04-1994	Cohen et al.		
	*A38	5,278,302	01-11-1994	Caruthers et al.		
	*A39	5,286,717	02-15-1994	Cohen et al.		
	*A40	5,321,131	06-14-1994	Agrawal et al.		
	*A41	5,366,878	11-22-1994	Pedersen et al.		
	*A42	5,399,676	03-21-1995	Froehler		
	*A43	5,403,711	04-04-1995	Walder et al.		
	*A44	5,405,938	04-11-1995	Summerton et al.		
	*A45	5,405,939	04-11-1995	Suhadolnik et al.		
	*A46	5,434,257	07-18-1995	Matteucci et al.		
	*A47	5,453,496	09-26-1995	Caruthers et al.		
	*A48	5,455,233	03-03-1995	Spielvogel et al.		
	*A49	5,466,677	11-14-1995	Baxter et al.		
	*A50	5,466,677	11-14-1995	Baxter et al.		
	*A51	. 5,470,967	11-28-1995	Hule et al.		
-	*A52	5,476,925	12-19-1995	Letsinger et al.		
	*A53	5,489,677	06-06-1996	Sanghvi et al.		
	*A54	5,491,133	02-13-1996	Walder et al.		
	*A55	5,519,126	05-21-1996	Hecht		
	*A56	5,536,821	07-16-1996	Agrawal et al.		
	*A57	5,539,082	07-23-1996	Nielsen et al.		
	*A58	5,541,306	07-30-1996	Agrawal et al.		
	*A59	5,541,307	07-30-1996	Cook et al.		
	*A60	5,545,806	08-13-1996	Lonberg et al.		
	*A61	5,545,807	08-13-1996	Surani et al.	·	
	*A62	5,550,111	08-27-1996	Suhadolnik et al.		
	*A63	5,561,225	01-01-1996	Maddry et al.		
	*A64	5,563,253	08-08-1996	Agrawal et al.		
	*A65	5,565,350	10-15-1996	Kmiec		
	*A66	5,569,825	10-29-1996	Lonberg et al.		
	*A67	5,571,799	05-05-1996	Tkachuk et al.		
	*A68	5,587,361	12-24-1996	Cook et al.		
	*A69	5,596,086	01-21-1997	Mateucci et al.		
_	*A70	5,602,240	02-11-1997	De Mesmaeker et al.		
	*					

Express Mail No.: EV 869858546 US Date of Deposit: September 22, 2006 Page 3 of 12 Attorney Docket No.: 24024-506 CON

*A71						
*A73	*A71	5,608,046	04-04-1997	Cook et al.	1	
*A74 \$.623.065	*A72	5,610,289	03-11-1997	Cook et al.		
*A75	*A73	5,618,704	08-08-1997	Sanghvi et al.		
*A76	*A74	5,623,065	04-22-1997	Cook et al.		
*A77 5,625,126 04-29-1997 Lonberg et al. *A78 5,631,219 05-20-1997 Rosenthal et al. *A79 5,633,360 05-27-1997 Bischofberger et al. *A80 5,633,425 05-27-1997 Lonberg et al. *A81 5,652,355 07-29-1997 Metelev et al. *A82 5,652,356 07-29-1997 Agrawal *A83 5,661,016 08-26-1997 Lonberg et al. *A84 5,663,312 02-02-1997 Chaturvedula *A85 5,677,437 10-14-1997 Teng et al. *A86 5,677,437 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Ledley et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Dubensky Jr. et al. *A96 5,789,545 04-04-1998 Dubensky Jr. et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,837,544 11-17-1998 Capon et al. *A99 5,837,544 11-17-1998 Capon et al. *A90 5,843,723 01-01-1998 Dubensky Jr. et al. *A90 5,843,723 01-01-1998 Dubensky Jr. et al. *A91 5,844,679 01-01-1998 Dubensky Jr. et al. *A92 5,851,832 12-22-1998 Weiss et al. *A103 5,851,832 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Klein et al.	*A75	5,623,070	04-22-1997	Cook et al.		
*A78 5,631,219 05-20-1997 Rosenthal et al. *A79 5,633,360 05-27-1997 Bischofberger et al. *A80 5,633,425 05-27-1997 Lonberg et al. *A81 5,652,335 07-29-1997 Metelev et al. *A82 5,652,335 07-29-1997 Agrawal *A83 5,661,016 08-26-1997 Lonberg et al. *A84 5,663,312 02-02-1997 Chaturvedula *A85 5,677,437 10-14-1997 Teng et al. *A86 5,677,439 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Dubensky Jr. et al. *A96 5,792,751 08-11-1998 Capon et al. *A97 5,814,482 09-29-1998 Ledley et al. *A98 5,830,760 03-03-1998 Dubensky Jr. et al. *A99 5,837,544 11-17-1998 Capon et al. *A90 5,843,723 01-01-1998 Dubensky Jr. et al. *A91 5,844,079 01-01-1998 Dubensky Jr. et al. *A92 5,837,544 11-17-1998 Capon et al. *A93 5,844,079 01-01-1998 Dubensky Jr. et al. *A94 5,849,723 01-01-1998 Dubensky Jr. et al. *A95 5,84,079 03-03-1998 Tsai et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Dubensky Jr. et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,834 12-22-1998 Weiss et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A76	5,625,050	04-29-1997	Beaton et al.		
*A79 5.633,360 05-27-1997 Bischofberger et al. *A80 5.633,425 05-27-1997 Lonberg et al. *A81 5.652,355 07-29-1997 Metelev et al. *A82 5.652,356 07-29-1997 Agrawal *A83 5.661,016 08-26-1997 Lonberg et al. *A84 5.663,312 02-02-1997 Chaturvedula *A85 5.677,437 10-14-1997 Teng et al. *A86 5.677,439 10-14-1997 Weis et al. *A87 5.700,922 12-23-1997 Cook *A88 5.714,331 03-03-1998 Buchardt et al. *A89 5.719,262 02-17-1998 Buchardt et al. *A90 5.741,899 04-21-1998 Capon et al. *A91 5.770,378 06-23-1998 Hwang et al. *A92 5.770,580 06-23-1998 Ledley et al. *A94 5.789,245 04-04-1998 Dubensky Jr. et al. *A95 5.789,543 04-04-1998 Ingham et al. *A96 5.792,751 08-11-1998 Capon et al. *A97 5.814,482 09-29-1998 Dubensky Jr. et al. *A98 5.830,760 03-03-1998 Tsai et al. *A99 5.837,544 11-17-1998 Capon et al. *A99 5.837,544 11-17-1998 Capon et al. *A99 5.837,544 11-17-1998 Capon et al. *A99 5.837,544 11-17-1998 Dubensky Jr. et al. *A99 5.837,544 11-17-1998 Capon et al. *A100 5.843,723 01-01-1998 Dubensky Jr. et al. *A101 5.844,079 01-01-1998 Ingham et al. *A102 5.851,832 12-22-1998 Matthews et al. *A103 5.851,834 12-22-1998 Matthews et al. *A104 5.877,207 02-02-1999 Klein et al. *A105 5.945,309 08-31-1999 Ni et al. *A106 5.952,345 09-14-1999 Klein et al.	 *A77	5,625,126	04-29-1997	Lonberg et al.		
*A80 5.633,425 05-27-1997 Lonberg et al. *A81 5.652,355 07-29-1997 Metelev et al. *A82 5.652,356 07-29-1997 Agrawal *A83 5.661,016 08-26-1997 Lonberg et al. *A84 5.663,312 02-02-1997 Chaturvedula *A85 5.677,437 10-14-1997 Teng et al. *A86 5.677,439 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5.714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,789,245 04-04-1998 Dubensky Jr. et al. *A94 5,789,245 04-04-1998 Ingham et al. *A95 5,789,543 04-04-1998 Unbensky Jr. et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Ingham et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Matthews et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al.	*A78	5,631,219	05-20-1997	Rosenthal et al.		
*A81 5.652,355 07-29-1997 Metelev et al. *A82 5.652,356 07-29-1997 Agrawal *A83 5.661,016 08-26-1997 Lonberg et al. *A84 5.663,312 02-02-1997 Chaturvedula *A85 5.677,437 10-14-1997 Teng et al. *A86 5.677,439 10-14-1997 Weis et al. *A87 5.700,922 12-23-1997 Cook *A88 5.714,331 03-03-1998 Buchardt et al. *A89 5.719,262 02-17-1998 Buchardt et al. *A90 5.741,899 04-21-1998 Capon et al. *A91 5.770,378 06-23-1998 Hwang et al. *A92 5.770,580 06-23-1998 Ledley et al. *A93 5.76.699 07-07-1998 Dubensky Jr. et al. *A94 5.789,245 04-04-1998 Dubensky Jr. et al. *A95 5.789,543 04-04-1998 Ledley et al. *A96 5.792,751 08-11-1998 Ledley et al. *A97 5.814,482 09-29-1998 Dubensky Jr. et al. *A98 5.830,760 03-03-1998 Tsai et al. *A99 5.837,544 11-17-1998 Capon et al. *A100 5.843,723 01-01-1998 Dubensky Jr. et al. *A101 5.844,079 01-01-1998 Dubensky Jr. et al. *A102 5.851,832 12-22-1998 Matthews et al. *A103 5.851,984 12-22-1998 Matthews et al. *A104 5.877,07 02-02-1999 Klein et al. *A105 5.945,309 08-31-1999 Klein et al.	*A79	5,633,360	05-27-1997	Bischofberger et al.		
*A82 5,652,356 07-29-1997 Agrawal *A83 5,661,016 08-26-1997 Lonberg et al. *A84 5,663,312 02-02-1997 Chaturvedula *A85 5,677,437 10-14-1997 Teng et al. *A86 5,677,439 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ledley et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,884 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A80	5,633,425	05-27-1997	Lonberg et al.		
*A83 5.661,016 08-26-1997 Lonberg et al. *A84 5.663,312 02-02-1997 Chaturvedula *A85 5.677,437 10-14-1997 Teng et al. *A86 5.677,439 10-14-1997 Weis et al. *A87 5.700,922 12-23-1997 Cook *A88 5.714,331 03-03-1998 Buchardt et al. *A89 5.719,262 02-17-1998 Buchardt et al. *A90 5.741,899 04-21-1998 Capon et al. *A91 5.770,378 06-23-1998 Hwang et al. *A92 5.770,580 06-23-1998 Ledley et al. *A93 5.776,699 07-07-1998 Klein et al. *A94 5.789,245 04-04-1998 Dubensky Jr. et al. *A95 5.789,543 04-04-1998 Ledley et al. *A96 5.792,751 08-11-1998 Ledley et al. *A97 5.814,482 09-29-1998 Dubensky Jr. et al. *A98 5.830,760 03-03-1998 Tsai et al. *A99 5.837,544 11-17-1998 Capon et al. *A100 5.843,723 01-01-1998 Dubensky Jr. et al. *A101 5.844,079 01-01-1998 Ingham et al. *A102 5.851,832 12-22-1998 Weiss et al. *A103 5.851,984 12-22-1998 Matthews et al. *A104 5.877,207 02-02-1999 Klein et al. *A105 5.945,309 08-31-1999 Ni et al. *A106 5.952,345 09-14-1999 Klein et al.	*A81	5,652,355	07-29-1997	Metelev et al.		
*A84 5,663,312 02-02-1997 Chaturvedula *A85 5,677,437 10-14-1997 Teng et al. *A86 5,677,439 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Ingham et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Klein et al. *A106 5,952,345 09-14-1999 Klein et al.	*A82	5,652,356	07-29-1997	Agrawal		
*A85 5,677,437 10-14-1997 Teng et al. *A86 5,677,439 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Ingham et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A83	5,661,016	08-26-1997	Lonberg et al.		
*A86 5.677,439 10-14-1997 Weis et al. *A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Ingham et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A84	5,663,312	02-02-1997	Chaturvedula		
*A87 5,700,922 12-23-1997 Cook *A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Ingham et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Klein et al. *A106 5,952,345 09-14-1999 Klein et al.	*A85	5,677,437	10-14-1997	Teng et al.		
*A88 5,714,331 03-03-1998 Buchardt et al. *A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Ingham et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Klein et al. *A106 5,952,345 09-14-1999 Klein et al.	*A86	5,677,439	10-14-1997	Weis et al.		
*A89 5,719,262 02-17-1998 Buchardt et al. *A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ledley et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A87	5,700,922	12-23-1997	Cook		
*A90 5,741,899 04-21-1998 Capon et al. *A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A88	5,714,331	03-03-1998	Buchardt et al.		
*A91 5,770,378 06-23-1998 Hwang et al. *A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A89	5,719,262	02-17-1998	Buchardt et al.		
*A92 5,770,580 06-23-1998 Ledley et al. *A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A90	5,741,899	04-21-1998	Capon et al.		
*A93 5,776,699 07-07-1998 Klein et al. *A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A91	5,770,378	06-23-1998	Hwang et al.		
*A94 5,789,245 04-04-1998 Dubensky Jr. et al. *A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A92	5,770,580	06-23-1998	Ledley et al.		
*A95 5,789,543 04-04-1998 Ingham et al. *A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A93	5,776,699	07-07-1998	Klein et al.		
*A96 5,792,751 08-11-1998 Ledley et al. *A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A94	5,789,245	04-04-1998	Dubensky Jr. et al.		
*A97 5,814,482 09-29-1998 Dubensky Jr. et al. *A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A95	5,789,543	04-04-1998	Ingham et al.		
*A98 5,830,760 03-03-1998 Tsai et al. *A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A96	5,792,751	08-11-1998	Ledley et al.		
*A99 5,837,544 11-17-1998 Capon et al. *A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A97	5,814,482		Dubensky Jr. et al.		
*A100 5,843,723 01-01-1998 Dubensky Jr. et al. *A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A98	5,830,760	03-03-1998	Tsai et al.		
*A101 5,844,079 01-01-1998 Ingham et al. *A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A99	5,837,544	11-17-1998	Capon et al.		
*A102 5,851,832 12-22-1998 Weiss et al. *A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A100	5,843,723	01-01-1998	Dubensky Jr. et al.		
*A103 5,851,984 12-22-1998 Matthews et al. *A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A101	5,844,079	01-01-1998	Ingham et al.		
*A104 5,877,207 02-02-1999 Klein et al. *A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A102	5,851,832	12-22-1998	Weiss et al.		
*A105 5,945,309 08-31-1999 Ni et al. *A106 5,952,345 09-14-1999 Klein et al.	*A103	5,851,984	12-22-1998	Matthews et al.	(8) - 50	
*A106 5,952,345 09-14-1999 Klein et al.	*A104	5,877,207	02-02-1999	Klein et al.		
	 *A105	5,945,309	08-31-1999	Ni et al.		
*A107 5,958,954 09-28-1999 Klein et al.	*A106	5,952,345	09-14-1999	Klein et al.		
	 *A107	5,958,954	09-28-1999	Klein et al.		

Express Mail No.: EV 869858546 US Date of Deposit: September 22, 2006

	*A108	5,990,329	11-23-1999	Klaus et al.	
	*A109	6,008,204	12-28-1999	Klein et al.	
	*A110	6,015,686	01-18-2000	Dubensky Jr. et al.	
	*A111	6,015,694	01-18-2000	Dubensky Jr. et al.	
	*A112	6,063,797	05-16-2000	Fesus et al.	
	*A113	6,077,947	06-20-2000	Capon et al.	
	*A114	6,090,810	07-18-2000	Klein et al.	
	*A115	6,117,850	09-12-2000	Patchen et al.	
	*A116	6,130,230	10-10-2000	Chambon et al.	
	*A117	6,133,309	10-17-2000	Bollag et al.	
	*A118	6,165,747	12-26-2000	Ingham et al.	
	*A119	6,218,128	04-17-2001	Klein et al.	_
	*A120	6,228,848	08-08-2001	Klein et al.	
	*A121	6,232,291	05-15-2001	Ni et al.	
	*A122	6,261,786	07-17-2001	Marigo et al.	
	*A123	6,270,964	07-07-2001	Michnick et al.	
	*A124	6,271,363	07-07-2001	Ingham et al.	
	*A125	6,284,540	04-04-2001	Milbrandt et al.	
	*A126	6,294,330	09-25-2001	Michnick et al.	
	*A127	6,306,575	10-23-2001	Thomas et al.	
	*A128	6,326,174	04-04-2001	Joyce et al.	
	*A129	6,329,169	12-11-2001	Ni et al.	
	*A130	6,338,942	01-15-2002	Kraus et al.	
	*A131	6,342,219	01-29-2002	Thorpe et al.	
	*A132	6,342,221	01-29-2002	Thorpe et al.	
	*A133	6,342,372	01-29-2002	Dubensky Jr. et al.	
	*A134	6,342,581	01-29-2002	Rosen et al.	
	*A135	6,372,210	04-16-2002	Brown	
	*A136	6,372,473	04-16-2002	Moore et al.	
	*A137	6,376,236	04-23-2002	Dubensky Jr. et al.	
	*A138	6,384,192	07-07-2002	Ingham et al.	
	*A139	6,887,704	03-03-2005	Peled et al.	
) 	*A140	6,962,698	08-08-2005	Peled et al.	

Page 4 of 12

Attorney Docket No.: 24024-506 CON

Express Mail No.: EV 869858546 US

Date of Deposit: September 22, 2006

Page 5 of 12

Attorney Docket No.: 24024-506 CON

	I 0'1. 11	· 1				HED APPLICATION DOCUMENTS					
Exam Initials	Cite No.		6. Published dication No.	Published Date	¹	Name of Patentee(s) or Applicant(s)		Class	Sub Class		ling Date If propriat
	*A141	200	2/0114789	08-22-200	02	Peled et al.				1	ургориш.
	*A142	200	3/0113913	06-19-200	03	Purton					
	*A143	200	4/0076603	04-22-200	04	Peled et al.					
	*A144	200	5/0008624	01-13-200	05	Peled et al.					
	*A145	200	5/0031595	02-10-200	05	Peled et al.					
	*A146	200	5/0054103	03-10-200	05	Peled et al.					
	*A147	200	5/0118150	02-02-200	05	Peled et al.					
	*A148	200	5/0214262	09-29-200	05	Peled et al.	+			 	······································
				F	OREI	GN PATENT DOCUMENTS			<u></u>		
Exam Initials	Cite No.	Foreign Office	Patent Docun Number	nent	Nam	ne of Patentee(s) or Applicant(s)		ate of ublication	n	Trans Yes	slation No
	B8	wo	89/02468		Mul	ligan et al.	03	3-23-198	9		
	B9	wo	89/05345			son et al.	06	5-15-198	9		
	B10	wo	89/07136		Wils	son et al.	08	3-10-198	9		
	B11	wo	92/07573		Rafi	eld et al.	05	-14-199	2		
	B12	wo	93/09220		Axe			5-13-199			
	B13	wo	97/41209			eadith et al.	11	-06-199	7		
	B14	wo	97/41224	·		aglia et al.		-06-199			
	B15	wo	99/07831			zari et al.		-18-199			
	B16	wo	99/18885			gouard et al.		-22-199			
	B17	wo	00/30635			erhill et al.		2-02-200			
	B18	wo	03/062369			d et al.		-31-200			
	B19	wo	03/078567			d et al.	_	-25-200			
	B20	wo	2004/0167			d et al.		-26-200			
	B21	WO	2004/0789	17 A2		d et al.		-16-200			
	B22 B23	EP	0 331 464			ma et al.	\rightarrow	-06-198			<u> </u>
	B24	AU AU	770896 759522			d et al.		-17-200 -30-199			
	<u> </u>	Αυ		P PRIOR AS		NON PATENT LITERATURE DOCUMEN	—		9		
Exam	Cite	Ī		· · · · · · · · · · · · · · · · · · ·							
Initials	No.		<u></u>	<u> </u>	<u> </u>	e), Publication, Volume, Page(s), Date, E					
	C100	Nature, 3	352: 815-818	1991.	•	ession in Mdx Mice After Intramuscular					
	C101	Potential	for Gene Th	erapy of He	moph	n Factor IX in Rabbit Hepatocytes by Rillia B", Proc. Natl. Acad. Sci. USA, 87:	6141	-6145, 1	990.		
	C102		t al. "Anemia n", Rinsho-Ke			in Eldery Patients Caused by Copper De 1280, 1994.	eficie	ncy for I	ong-Term	Eterna	al
	C103	Belovari	et al. "Differ	entiation of	Rat N	Neural Tissue in A Serum-Free Embryo (urnal, 42(6): 611-617, 2001. Abstract.	Cultur	re Mode	Followed	by In	Vivo
	C104	Beradi et	t al. "Individu	al CD34+C	D381	owCD19-CD10- Progenitor Cells From d, 89(10): 3554-3564, 1997.	Huma	an Cord	Blood Gei	nerate E	3

Express Mail No.: EV 869858546 US

Date of Deposit: September 22, 2006

Page 6 of 12

Attorney Docket No.: 24024-506 CON

Ever	Cito Ma	U.S. PUBLISHED APPLICATION DOCUMENTS									
Exam Initials	Cite No.	U.S. Published Application No.	Published Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriat				
-	C105	Berkner "Development of Adenovirus Vectors for the Expression of Heterologous Genes", BioTechniques, 6(7): 616-629, 1988.									
	C106	Bi et al. "Effect of Lactoferrin on Proliferation and Differentiation of the Jurkat Human Lymphoblastic T Cell Line", Arch. Immunol. Ther. Exp., 45(4): 315-320, 1997. Abstract.									
	C107		Bird et al. "Single-Chain Antigen-Binding Proteins", Science, 242: 423-426, 1988.								
	C108	Boerner et al. "Produc	Boerner et al. "Production of Antigen-Specific Human Monoclonal Antibodies From In Vitro-Primed Human Splenocytes", The Journal of Immunology, 147(1): 86-95, 1991.								
	C109										
	C110	Brigham et al. "Rapid Communication: In Vivo Transfection of Murine Lungs With A Functioning Prokaryotic Gene Using A Liposome Vehicle", The American Journal of the Medical Sciences, 298(4): 278-281, 1989.									
	C111	Brugger et al. "Ex Viv	o Expansion of	Enriched Peripheral Blood CD34+ Progeni terferon-γ, and Erythropoietin", Blood, 81(1	tor Cells b	y Stem Cell	Factor,				
	C112			nal Mapping and Characterization of the Hunc Acids Research, 22(15): 3167-3173, 1994.		-Regulatory					
	C113	Buskin et al. "Identific Muscle Creatine Kina	cation of A Myc se Gene", Mole	ocyte Nuclear Factor That Binds to the Musc cular and Cellular Biology, 9(6): 2627-2640	cle-Specific , 1989.						
	C114		Cakir-Kiefer et al. "Kinetic Competence of the cADP-Ribose-CD38 Complex as An Intermediate in the CD38/NAD+ Glycohydrolase-Catalysed Reactions: Implication for CD38 Signalling", Biochemical Journal, 358: 399-406, 2001.								
·	C115		Casal et al. "In Utero Transplantation of Fetal Liver Cells in the Mucopolysaccharidosis Type VII Mouse Results in Low-Level Chimerism, But Overexpression of Beta-Glucuronidase Can Delay Onset of Clinical Signs", Blood,								
	C116	Cepko "Overview of the Retrovirus Transduction System", Short Protocols in Molecular Biology, Unit 9.10-9.14: 9-41 - 9-57, 1984.									
	C117			(FGF) Signaling Through PI 3-Kinase and 3750-3756, 2000. P.3752-3755.	Akt/PKB I	s Required 1	or Embryoid				
	C118		Chen et al. "Therapeutic Benefit of Intravenous Administration of Bone Marrow Stromal Cells After Cerebral Ischemia in Rats", Stroke, 32(4): 1005-1011, 2001.								
	C119			Peptide AcSDKP on the Proliferative State or pril", Stem Cells, 15(6): 455-460, 1997.	f Hematop	oietic Stem	Cells in the				
	C120	Chowdhury et al. "Lor Deficient Rabbits", Sc		rement of Hypercholesterolemia After Ex Vi 2-1805, 1991.	vo Gene T	herapy in L	DLR-				
	C121			y: Adenovirus Enhancement of Receptor-Me Proc. Natl. Acad. Sci. USA, 90: 2122-2126,		ne Delivery	and				
	C122		rus Enhancemer	nt of Transferrin-Polylysine-Mediated Gene		Proc. Natl.	Acad. Sci.				
	C123			d Liver-Specific mRNA Expression in Facurnal of Pathology, 147: 1633-1648, 1995. A		thelial Proge	enitor Cells				
	C124	Dahl et al. "Tranforma	tion of Hemato	poietic Cells by the Ski Oncoprotein Involve Sci. USA, 95(19): 11187-11192, 1998.		on of Retino	oic Acid				
	C125			Myoblasts: Long-Term Expression of Facto Acad. Sci. USA, 89: 10892-10895, 1992.	r IX Prote	in Following	,				
	C126		d Neonatal Patt	erns of Human Globin Gene Expressioon A	re Recapitu	ılated in Liq	uid				
	C127		Efficient Gener	ration of Recombinant Retroviruses With Ar	nphotropic	and Ecotro	pic Host				
	C128		Radiation Activa	ates Transcription of the EGR1 Gene Via CA	ArG Eleme	nts", Proc. N	latl. Acad.				

Express Mail No.: EV 869858546 US

Date of Deposit: September 22, 2006

Page 7 of 12

Attorney Docket No.: 24024-506 CON

C129	De Luca et al. "Retinoic Acid Is A Potent Regulator of Growth Plate Chondrogenesis", Endocrinology, 141(1): 346-353, 2000. Abstract.
C130	De Wynter et al. "CD34+AC133+ Cells Isolated From Cord Blood Are Highly Enriched in Long-Term Culture-Initiating Cells, NOD/SCID-Repopulating Cells and Dendritic Cell Progenitors", Stem Cells, 16: 387-396, 1998.
C131	Defacque et al. "Expression of Retinoid X Receptor Alpha Is Increased Upon Monocytic Cell Differentiation", Biochemical and Biophysical Research Communications, 220: 315-322, 1996.
C132	Ebner et al. "Distinct Roles for PI3K in Proliferation and Survival of Oligodendrocyte Progenitor Cells", Journal of Neuroscience Research, 62: 336-345, 2000. P.338-344.
C133	Eglitis et al. "Gene Expression in Mice After High Efficiency Retroviral-Mediated Gene Transfer", Science, 230: 1395-1398, 1985.
C134	Englisch et al. "Chemically Modified Oligonucleotides as Probes and Inhibitors", Angewandte Chemie (International Edition in English), 30(6): 613-629, 1991.
C135	Feldman "Israeli Start-Up Gamida-Cell To Receive Prize", GLOBES - ONLINE, 2004.
C136	Ferry et al. "Retroviral-Mediated Gene Transfer Into Hepatocytes In Vivo", Proc. Natl. Acad. Sci. USA, 88: 8377-8381, 1991.
C137	Fibach et al. "Growth of Human Normal Erythroid Progenitors in Liquid Culture: A Comparison With Colony Growth in Semisolid Culture", International Journal of Cell Cloning, 9: 5764, 1991.
C!38	Fibach et al. "Normal Differentiation of Myeloid Leukemic Cells Induced by Differentiation-Indicing Protein", Nature, 237: 276-278, 1972.
C139	Fibach et al. "Proliferation and Maturation of Human Erythroid Progenitors in Liquid Culture", Blood, 73(1): 100-103, 1989. Abstract.
C140	Fibach et al. "Retinoic Acid Antagonist Inhibits CD38 antigen Expression on Human Hematopoietic Cells", Blood, 100(11): 172A & 44th Annual Meeting of the American Society of Hematology, 2002. Abstract.
C141	Fibach et al. "The Two-Step Liquid Culture: A Novel Procedure for Studying Maturation of Human Normal and Pathological Erythroid Precursors", Stem Cells, 11(Suppl.1): 36-41, 1993. Abstract.
C142	Filvaroff et al. "Functional Evidence for An Extracellular Calcium Receptor Mechanism Triggering Tyrosine Kinase Activation Associated With Mouse Keratinocyte Differentiation", The Journal of Biological Chemistry, 269(34): 21735-21740, 1994.
C143	Fishwild et al. "High-Avidity Human IgGk Monoclonal Antibodies From A Novel Strain of Minilocus Transgenic Mice", Nature Biotechnology, 14: 845-851, 1996.
C144	Flores et al. "Akt-Mediated Survival of Oligodendrocytes Induced by Neuregulins", The Journal of Neuroscience, 20(20): 7622-7630, 2000. P.7624-7629.
C145	Flotte et al. "Expression of the Cystic Fibrosis Transmemebrane Conductance Regulators From A Novel Adeno-Associated Virus Promoter", The Journal of Biological Chemistry, 268(5): 3781-3790, 1993.
C146	Flotte et al. "Gene Expression From Adeno-Associated Virus Vectors in Airways Epithelial Cells", Amercan Journal of Respiratory Cell and Molecular Biology, 7: 349-356, 1992.
C147	Fosmire "Zinc Toxicity", American Journal of Clinical Nutrition, 51(2): 225-227, 1990. Abstract.
C148	Gagnon et al. "Activation of Protein Kinase B and Induction of Adipogenesis by Insulin in 3T3-L1 Preadipocytes", Diabetes, 48: 691-698, 1999. P.693-697.
C149	Gould-Fogerite et al. "Chimerasome-Mediated Gene Transfer In Vitro and In Vivo", Gene, 84: 429-438, 1989.
C150	Grande et al. "Physiological Levels of 1Alpha, 25 Dihydroxyvitamin D3 Induce the Monocytic Commitment of CD34+ Hematopoietic Progenitors", J. Leukoc. Biol., 71(4): 641-651, 2002.
C151	Gur et al. "Toelrance Induction by Megadose Hematopoietic Progenitor Cells: Expansion of Veto Cells by Short- Term Culture of Purified Human CD34+ Cells", Blood, 99: 4174-4181, 2002.
C152	Haj-Ahmad et al. "Development of A Helper-Independent Human Adenovirus Vector and Its Use in the Transfer of the Herpes Simplex Virus Thymidine Kinase Gene", Journal of Virology, 57(1): 267-274, 1986.
C153	Hamilton "Stem Cell Technology to Treat Leukemia Patients Show Promise", The Wall Street Journal, ONLINE, 2003.
C154	Hammond et al. "Suppression of In Vitro Granulocytopoiesis by Captopril and Penicillamine", Experimental Hematology, 16(8): 674-680, 1988.
C155	Hatayama et al. "Regulation of HSP70 Synthesis Induced by Cupric Sulfate and Zinc Sulfate in Thermotolerant HeLa Cells", Journal of Biochemistry, Tokyo, 114(4): 592-597, 1993. Abstract.
C156	Haylock et al. "Ex-Vivo Expansion and Maturation of Peripheral Blood CD34+ Cells Into the Myeloid Lineage", Blood, 80(5): 1405-1412, 1992.

Express Mail No.: EV 869858546 US

Date of Deposit: September 22, 2006

Attorney Docket No.: 24024-506 CON

C157	Hermonat et al. "Use of Adeno-Associated Virus as A Mammalian DNA Cloning Vector: Transduction of Neomycin Resistance Into Mammalian Tissue Culture Cells", Proc. Natl. Acad. Sci. USA, 81: 6466-6470, 1984.
C158	Herz et al. "Adenovirus-Mediated Transfer of Low Density Lipoprotein Receptor Gene Acutely Accelerates Cholesterol Clearence in Normal Mice", Proc. Natl. Acad. Sci. USA, 90: 2812-2816, 1993.
C159	Heuchel et al. "The Transcription Factor MTF-1 Is Essential for Basal and Heavy Metal-Induced Metallothionein Gene Expression", The EMBO Journal, 13(12): 2870-2875, 1994.
C160	Hida et al. "Existence of Retinoic Acid-Receptor-Independent Retinoid X-Receptor-Dependent Pathway in Myeloid Cell Function", Jpn. J. Pharmacol., 85(1): 60-69, 2001.
C161	Hirose et al. "Identification of A Transposon-Related RNA Down-Regulated by Retinoic Acid in Embryonal Carcinoma and Embryonic Stem Cells", Exp. Cell Res., 221(2): 294-300, 1995. Abstract.
C162	Hmama et al. "1-Alpha, 25-Dihydroxyvitamin D3-Induced Myeloid Cell Differentiation Is Regulated by A Vitamin D Receptor-Phospatidylinositol 3-Kinase Signaling Complex", Journal of Experimental Medicine, 190(11): 1583-1594, 1999.
C163	Hoffman et al. "Zinc-Induced Copper Deficiency", Gastroenterology, 94(2); 508-512, 1988.
C164	Holleman "Triethylene Tetramine, CAS No. 112-24-3", Chemical Hazard Information Profile Draft Report, 1982. abstract.
C165	Hoogenboom et al. "By-Passing Immunisation. Human Antibodies From Synthetic Repertoires of Germline VH Gene Segments Rearranged In Vitro", Journal of Molecular Biology, 227: 381-388, 1992.
C166	Hottinger et al. "The Copper Chelator D-Penicillamine Delays Onset of Disease A Extends Survival in A Transgenic Mouse Model of Familial Amyotrophic Lateral Sclerosis", European Journal of Neuroscience, 9(7): 1548-51, 1997. Abstract.
C167	Huang et al. "Differentiation of Human U937 Promonocytic Cells Is Impaired by Moderate Copper Deficiency", Experimental Biology and Medicine, 226(3): 222-228, 2001.
C168	Huber et al. "Retroviral-Mediated Gene Therapy for the Treatment of Hepatocellular Carcinoma: An Innovative Approach for Cancer Therapy", Proc. Natl. Acad. Sci. USA, 88: 8039-8043, 1991.
C169	Hutvágner et al. "RNAi: Nature Abhors A Double-Strand", Current Opinion in Genetics & Development, 12: 225-232, 2002.
C170	Hwu et al. "Functional and Molecular Characterization of Tumor-Infiltrating Lymphocytes Transduced With Tumor Necrosis Factor-α cDNA for the Gene Therapy of Cancer in Humans", The Journal of Immunology, 150(9): 4104-4115, 1993.
C171	Inbar et al. "Localization of Antibody-Combining Sites Within the Variable Portions of Heavy and Light Chains", Proc. Natl. Acad. Sci. USA, 69(9): 2659-2662, 1972.
C172	Itoh et al. "Inhibition of Urokinase Receptor (uPAR) Expression by RNA-Cleaving Catalytic DNA (DNAzyme) Containing Antisense uPAR", Molecular Therapy, 5(5/Part 2): S134, 2002.
C173	Jiang et al. "Phosphatidylinositol 3-Kinase Signaling Mediates Angiogenesis and Expression of Vascular Endothelial Growth Factor in Endothelial Cells", PNAS, 97(4): 1749-1753, 2000.
C174	Johnson et al. "Synthesis and Biological Activity of High-Affinity Retinoic Acid Receptor Antagonists", Bioorganic & Medicinal Chemistry, 7(7): 1321-1338, 1999.
C175	Johnson et al. "The Cytokines IL-3 and GM-CSF Regulate the Transcriptional Activity of Retinoic Acid Receptors in Different In Vitro Models of Myeloid Differentiation", Blood, 99(3): 746-753, 2002.
C176	Jones et al. "Replacing the Complementarity-Determining Regions in A Human Antibody With Those From A Mouse", Nature, 321: 522-525, 1986.
C177	Kang et al. "Retinoic Acid and Its Receptors Repress the Expression and Transactivation Functions of Nur77: A Possible Mechanism for the Inhibition of Apoptosis by Retinoic Acid", Experimental Cell Research, 256: 545-554, 2000.
C178	Kastner et al. "Positive and Negative Regulation of Granulopoiesis by Endogenous RARalpha", Blood, 97(5): 1314-1320, 2001. Abstract.
C179	Kaufman et al. "Translational Efficency of Polycistronic mRNAs and Their Utilization to Express Heterologous Genes in Mammalian Cells", The EMBO Journal, 6(1): 187-193, 1987.
C180	Kay et al. "Hepatic Gene Therapy: Persistent Expression of Human α1-Antitrypsin in Mice After Direct Gene Delivery In Vivo", Human Gene Therapy, 3: 641-647, 1992.
C181	Khachigian "DNAzymes: Cutting A Path to A New Class of Therapeutics", Current Opinion in Molecular Therapeutics, 4(2): 119-121, 2002.
C182	Kim "Differentiation and Identification of the Two Catalytic Metal Binding Sites in Bovine Lens Leucine Aminopeptidase by X-Ray Crystallography", Proc. Natl. Acad. Sci. USA, 90(11): 5006-5010, 1993.

Express Mail No.: EV 869858546 US

Date of Deposit: September 22, 2006

Page 9 of 12

Attorney Docket No.: 24024-506 CON

	C183	Kishimoto et al. "Molecular Mechanism of Human CD38 Gene Expression by Retinoic acid. Identification of Retinoic Acid Response Elemen in the First Intron", J. Biol. Chem., 273(25): 15429-15434, 1998. Abstract.
	C184	Kizaki et al. Regulation of Manganese Superoxide Dismutase and Other Antioxidant Genes in Normal and
		Leukemic Hematopoietic Cells and Their Relationship to Cytotoxicity by Tumor Necrosis Factor", Blood, 82(4): 1142-1150, 1993.
	C185	Koizumi et al. "Large Scale Purification of Human Blood CD34+ Cells From Cryopreserved Peripheral Blood
		Stem Cells, Using A Nylon-Fiber Syringe System and Immunomagnetic Microspheres", Bone Marrow
		Transplantation, 26: 787-793, 2000.
	C186	Lapidot et al. "Cytokine Stimulation of Multilineage Hematopoiesis From Immature Human Cells Engrafted in
		SCID Mice", Science, 255: 1137-1141, 1992.
	C187	Larrick et al. "PCR Amplification of Antibody Genes", Methods: A Companion to Methods in Enzymology, 2(2): 106-110, 1991.
-	C188	Lawlor et al. "Coordinate Control of Muscle Cell Survival by Distinct Insulin-Like Growth Factor Activated
	1 0100	Signaling Pathways", The Journal of Cell Biology, 151(6): 1131-1140, 2000. P.1133-1139.
	C189	Lee et al. "Effect of Vitamin D Analog, EB1089, on Hematopoietic Stem Cells From Normal and Myeloid
	0.03	Leukemia Blasts", Leukemia, 10: 1751-1757, 1996.
	C190	Lemarchand et al. "Adenovirus-Mediated Transfer of A Recombinant Human al-Antitrypsin cDNA to Human
		Endothelial Cells", Proc. Natl. Acad. Sci. USA, 89: 6482-6486, 1992.
	C191	Lewandowski et al. "Phosphatidylinositol 3-Kinases Are Involved in the All-Trans Retinoic Acid-Induced
	Ì	Upregulation of CD38 Antigen on Human Haematopoietic Cells", British Journal of Hematology, 118(2): 535-
		544, 2002. Fig.8.
	C192	Li et al. "Activation of Phosphatidylinositol-3 Kinase (PI-3K) and Extracellular Regulated Kinases (Erk1/2) Is
		Involved in Muscarinic Receptor-Mediated DNA Synthesis in Neural Progenitor Cells", The Journal of
		Neuroscience, 21(5): 1569-1579, 2001. P.1572-1578.
	C193	Lonberg et al. "Antigen-Specific Human Antibodies From Mice Comprising Four Distinct Genetic
<u> </u>	C104	Modifications", Nature, 368: 856-859, 1994.
	C194	Lonberg et al. "Human Antibodies From Transgenic Mice", International Review in Immunology, 13: 65-93, 1995.
	C195	Lutton et al. "Zinc Porphyrins: Potent Inhibitors of Hematopoieses in Animal and Human Bone Marrow", Proc.
		Natl. Acad. Sci. USA, 94: 1432-1436, 1997.
	C196	Mader et al. "A Steroid-Inducible Promoter for the Controlled Overexpression of Cloned Genes in Eukaryotic
	<u> </u>	Cells", Proc. Natl. Acad. Sci. USA, 90: 5603-5607, 1993.
	C197	Manome et al. "Coinduction of C-Jun Gene Expression and Internucleosomal DNA Fragmentation by Ionizing
	<u> </u>	Radiation", Biochemistry, 32: 10607-10613, 1993.
	C198	Mar et al. "A Conserved CATTCCT Motif Is Required for Skeletal Muscle-Specific Activity of the Cardiac
	ļ	Troponin T Gene Promoter", Proc. Natl. Acad. Sci. USA, 85: 6404-6408, 1988.
	C199	Marks et al. "By-Passing Immunization. Human Antibodies From V-Gene Libraries Displayed on Phage", Journal
<u> </u>	0000	of Molecular biology, 222: 581-597, 1991.
	C200	Marks et al. "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", Bio/Technology, 10: 779-783, 1992.
	C201	Martelli et al. "Transplants Across Human Leukocyte Antigen Barriers", Seminars in Hematology, 39(1): 48-56,
1		2002.
	C202	Matzner et al. "Bone Marrow Stem Cell Gene Therapy of Arylsulfatase A-Deficient Mice, Using An Arylsulfatase
		A Mutant That Is Hypersecreted From Retrovirally Transduced Donor-Type Cells", Human Gene Therapy, 12:
		1021-1033, 2001.
	C203	McLaughlin et al. "Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures",
<u></u>	<u> </u>	Journal of Virology, 62(6): 1963-1973, 1988.
	C204	Mehta et al. "Retinoid-Mediated Signaling Pathways in CD38 Antigen Expression in Myeloid Leukemia Cells",
<u> </u>		Leukemia and Lymphoma, 32(5/6): 441-449, 1999.
	C205	Merck & Co. "The Merck Index, An Encyclopedia of Chemicals, Drugs and Biologicals", 10th Ed.(3742): 549, 1983.
	C206	Miller "Progress Toward Human Gene Therapy", Blood, The Journal of the American Society of Hematology, 76(2): 271-278, 1990.
—	C207	Mills et al. "Regulation of Retinoid-Induced Differentiation in Embryonal Carcinoma PCC4.Aza 1 R Cells:
1		Effects of Retinoid-Receptor Selective Ligands", Cell Growth Differ., 7(3): 327-337, 1996. Abstract.
		1

Express Mail No.: EV 869858546 US

Date of Deposit: September 22, 2006

Page 10 of 12

Attorney Docket No.: 24024-506 CON

C208	Morier-Teissier et al. "Synthesis and Antitumor Properties of An Anthraquinone Bisubstituted by the Copper Chelating Peptide Gly-Gly-L-His", Journal of Medical Chemistry, 36: 2084-2090, 1993. Abstract.
C209	Morrison "Success in Specification", Nature, 368(6474): 812-813, 1994.
C210	Muramatsu et al. "Reversible Integration of the Dominant Negative Retinoid Receptor Gene for Ex Vivo Expansion of Hematopoietic Stem/Progenitor Cells", Biochem. Biophys. Res. Commun., 285(4): 891-896, 2001. Abstract.
C211	Muzyczka "Use of Adeno-Associated Virus as A General Transduction Vector for Mammalian Cells", Current Topics in Microbiology and Immunology, 158: 97-129, 1992.
C212	Narita et al. "Cardiomycyte Differentiation by GATA-4-Deficient Embryonic Stem Cells", Development, 122(19): 3755-3764, 1996.
C213	Neuberger "Generating High-Avidity Human Mabs in Mice", Nature Biotechnology, 14: 826, 1996.
C214	Nicolau et al. "Liposomes as Carriers for In Vivo Gene Transfer and Expression", Methods in Enzymology, 149(Chap. 16): 157-176, 1987.
C215	Okazaki et al. "Characteristics and Partial Purification of A Novel Cytosolic, Magnesium-Independent, Neutral Sphingomyelinase Activated in the Early Signal Transduction of 1a,25-Dihydroxyvitamin D3-Induced HL-60 Cell Differentiation", The Journal of Biological Chemistry, 269(6): 4070-4077, 1994.
 C216	Oliveras et al. "Copper As An Essential Nutrient", Inst. of Nutrition and Food Tech., Chile, 1996.
 C217	Pack et al. "Improved Bivalent Miniantibodies, With Identical Avidity as Whole Antibodies, Produced by High Cell Density Fermentation of Escherichia Coli", Bio/Technology, 11: 1271-1277, 1993.
C218	Peled et al. "Cooper Chelators Sustain Long-Term Expansion of Cord-Blood CD 34 + Cultures Initiated With IL-3 and G-CSF - Late Acting, Differentiation-Inducing Cytokines", Blood, 96(1): 773a, Abstract 3343, 2000.
C219	Peled et al. "Regulation of Long-Term Expansion of Hemopoietic Stem/Progenitor Cells (HPC) by Intracellular Copper Content", Blood, 96(Part 1): 776a-777a, 2000.
C220	Percival et al. "Copper Is Required to Maintain Cu/Zn-Superoxide Dismutase Activity During HL-60 Cell Differentiation", Proc. Soc. Exp. Biol. Med., 203: 78-83, 1993.
C221	Petersen et al. "Hepatic Oval Cells Express the Hematopoietic Stem Cell Marker Thy-1 in the Rat", Hepatology, 27(2): 433-445, 1998.
C222	Pickart et al. "Growth Modulating Plasma Tripeptide May Function by Facilitating Copper Uptake Into Cells", Nature, 288(18/25): 715-717, 1980. Abstract. P.716, Col.2, Line1.
C223	Podestà et al. Extracellular Cyclic ADP-Ribose Increases Intracellular Free Calcium Concentration and Stimulates Proliferation of Human Hematopoietic Progenitors", FASEB Journal, 14(5): 680-690, 2000. Fig. 1.
C224	Porter "The Hydrolysis of Rabbit γ-Globulin and Antibodies With Crystalline Papain", Biochemical Journal, 73: 119-126, 1959.
C225	Presta "Antibody Engineering", Current Opinion in Structural Biology, 2: 593-596, 1992.
C226	Purton et al. "All-Trans Retinoic Acid Enhances the Long-Term Repopulating Activity of Cultured Hematopoietic Stem Cells", Blood, 95(2): 470-477, 2000. Abstract.
C227	Purton et al. "All-Trans Retinoic Acid Facilities Oncoretrovirus-Mediated Transduction of Hematopoietic Repopulating Stem Cells", J. Hematother. Stem Cell Res., 10(8): 815-825, 2001. Abstract.
 C228	Quantin et al. "Adenovirus as An Expression Vector in Muscle Cells In Vivo", Proc. Natl. Acad. Sci. USA, 89: 2581-2584, 1992.
C229	Ratajczak et al. "Effect of Basic (FGF-2) and Acidic (FGF-1) Fibroblast Growth Factors on Early Haemopoietic Cell Development", British Journal of Hematology, 93: 772-782, 1996.
C230	Reeves et al. "High Zinc Concentrations in Culture Media Affect Copper Uptake and Transport in Differentiated Human Colon Adenocarcinoma Cells", Journal of Nutrition, 126(6): 1701-1712, 1996. Abstract.
C231	Reid et al. "Interactions of Tumor Necrosis Factor With Granulocyte-Macrophage Colony-Stimulating Factor and Other Cytokines in the Regulation of Dendritic Cell Growth In Vitro From Early Bipotent CD34+ Progenitors in Human Bone Marrow", Journal of Immunology, 149(8): 2681-2688, 1992. Abstract. P.2686, Col.1, 2nd §, P.2682, Col.1, 2nd §.
C232	Riechmann et al. "Reshaping Human Antibodies for Therapy", Nature, 332: 323-327, 1988.
C233	Rosenfeld et al. "Adenovirus-Mediated Transfer of A Recombinant α1-Antitrypsin Gene to the Lung Epithelium In Vivo", Science, 252: 431-434, 1991.
C234	Rosenfeld et al. "In Vivo Transfer of the Human Cystic Fibrosis Transmembrane Conductance Regulator Gene to the Airway Epithelium", Cell, 68: 143-155, 1992.
C235	Rowley et al. "Isolation of CD34+ Cells From Blood Stem Cell Components Using the Baxter Isolex System", Bone Marrow Transplantation, 21: 1253-1262, 1998.

Express Mail No.: EV 869858546 US
Date of Deposit: September 22, 2006
Page 11 of 12
Attorney Docket No.: 24024-506 CON

	C236	Rusten et al. "The RAR-RXR as Well as the RXR-RXR Pathway Is Involved Signaling Growth Inhibition of Human CD34+ Erythroid Progenitor Cells", Blood, 87(5): 1728-1736, 1996. Abstract.
	C237	Sammons et al. "Mechanisms Mediating the Inhibitory Effect of All-Trans Retinoic Acid on Primitive
		Hematopoietic Stem Cells in Human Long-Term Bone Marrow Culture", Stem Cells, 18(3): 214-219, 2000.
	C238	Samulski et al. "Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression", Journal of Virology, 63(9): 3822-3828, 1989.
	C239	Sato et al. "In Vitro Expansion of Human Peripheral Blood CD34+ Cells", Blood, 82(12): 3600-3609, 1993.
	C240	Sauve et al. "Mechanism-Based Inhibitors of CD38: A Mammalian Cyclic ADP-Ribose Synthetase",
		Biochemistry, 41(26): 8455-8463, 2002.
ŀ	C241	Schmetzer et al. "Effect of GM-CSF, 1,25-Dihydroxycholecalciferol (Vit. D) and All-Trans-Retinocin Acid
		(ATRA) on the Proliferation and Differentiation of MDS-Bone Marrow (BM)-Cells In Vitro", Hematology, 2: 11-19, 1997.
	C242	Schwartz et al. "In Vitro Myelopoiesis Stimulated by Rapid Medium Exchange and Supplementation With
		Hematopoietic Growth Factors", Blood, 78(12): 3155-3161, 1991.
	C243	Seed "An LFA-3 cDNA Encodes A Phospholipid-Linked Membrane Protein Homologous to Its Receptor CD2", Nature, 329: 840-842, 1987.
	C244	Sekhar et al. "Retroviral Transduction of CD34-Enriched Hematopoietic Progenitor Cells Under Serum-Free
		Conditions", Human Gene Therapy, 7: 33-38, 1996.
	C245	Selden "Transfection Using DEAE-Dextran", Short Protocols in Molecular Biology, Unit 9.2: 9-9 - 9-11, 1984.
	C246	Selden et al. "Optimization of Transfection", Short Protocols in Molecular Biology, Unit 9.4: 262-263, 1984.
	C247	Sergeant et al. "Iron and Copper Requirements for Proliferation and Differentiation of A Human Promyelocytic
		Leukemia Cell Line (HL-60)", Journal of Cellular Physiology, 163(3): 477-485, 1995.
ļ	C248	Shimakura et al. "Murine Stromal Cell Line HESS-5 Maintains Reconstituting Ability of Ex Vivo-Generated
		Hematopoietic Stem Cells From Human Bone Marrow and Cytokine-Mobilized Peripheral Blood", Stem Cells, 18: 183-189, 2000.
	C249	Slavin et al. "Donor Lymphocyte Infusion: The Use of Alloreactive and Tumor-Reactive Lymphocytes for
		Immunotherapy of Malignant and Nonmalignant Diseases in Conjunction With Allogeneic Stem Cell
	<u> </u>	Transplantation", Journal of Hematotherapy & Stem Cell Research, 11: 265-276, 2002.
	C250	Slavin et al. "Treatment of Leukemia by Alloreactive Lymphocytes and Nonmyeloablative Stem Cell .
		Transplantation", Journal of Clinical Immunology, 22(2): 64-69, 2002.
	C251	Spencer et al. "Controlling Signal Transduction With Synthetic Ligands", Science, 262: 1019-1024, 1993.
	C252	Szilvassy et al. "Differential Homing and Engraftment Properties of Hematopoetic Progenitor Cells From Murine Bone Marrow Mobilized Peripheral Blood Cells and Fetal Liver", Blood, 98(7): 2108-2115, 2001.
	C253	Takeshita et al. "Selective Stimulation by Ceramide of the Expression of the α Isoform of Retinoic Acid and Retinoid X Receptors in Osteoblastic Cells", Journal of Biological Chemistry, 275(41): 32220-32226, 2000.
	C254	Todisco et al. "CD38 Ligation Inhibits Normal and Leukemic Myelopoiesis", Blood, 95(2): 535-542, 2000.
	-	Abstract.
	C255	Tratschin et al. "A Human Parvovirus, Adeno-Associated Virus, as A Eucaryotic Vector: Transient Expression
		and Encapsidation of the Procaryotic Gene for Chloramphenicol Acetyltransferase", Molecular and Cellular
		Biology, 4(10): 2072-2081, 1984.
	C256	Tratschin et al. "Adeno-Associated Virus Vector for High-Frequency Integration, Expression, and Rescue of
		Genes in Mammalian Cells", Molecular and Cellular Biology, 5(11): 3251-3260, 1985.
	C257	Tratschin et al. "Genetic Analysis of Adeno-Associated Virus: Properties of Deletion Mutants Constructed In
		Vitro and Evidence for An Adeno-Associated Virus Replication Function", Journal of Virology, 51(3): 611-619, 1984.
	C258	Tuba et al. "Synthesis and Structure - Activity Relationships of Neuromuscular Blocking Agents", Current
		Medicinal Chemistry, 9: 1507-1536, 2002.
	C259	Van Beusechem et al. "Long-Term Expression of human Adenosine Deaminase in Rhesus Monkeys Transplanted With Retrovirus-Infected Bone-Marrow Cells", Proc. Natl. Acad. Sci. USA, 89: 7640-7644, 1992.
	C260	Verfaillie "Can Human Hematopoietic Stem Cells Be Cultured Ex Vivo?", Stem Cells, 12(5): 466-476, 1994. Abstract.
	C261	Verhoeyen et al. "Reshaping Human Antibodies: Grafting An Antilysozyme Activity", Science, 239: 1534-1536,
	5201	1988.
	<u> </u>	1

Express Mail No.: EV 869858546 US

Page 12 of 12

Date of Deposit: September 22, 2006

Attorney Docket No.: 24024-506 CON

C262	Verlinden et al. "Interaction of Two Novel 14-Epivitamin D3 Analogs With Vitamin D3 Receptor-Retinoid X
	Receptor Heterodimers on Vitamin D3 Response Elements", Journal of Bone and Mineral Research, 16(4): 625-638, 2001.
C263	Wall et al. "Inhibition of the Intrinsic NAD+ Glycohydrolase Activity of CD38 by Carbocyclic NAD Analogues", Biochemical Journal, 335(3): 631-636, 1998.
C264	Wang et al. "PH-Sensitive Immunoliposomes Mediate Target-Cell-Specific Delivery and Controlled Expression of A Foreign Gene in Mouse", Proc. Natl. Acad. Sci. USA, 84: 7851-7855, 1987.
C265	Wendling et al. "Retinoid X Receptor Are Essential for Early Mouse Development and Placentogenesis", Proc. Natl. Acad. Sci. USA, 96(2): 547-551, 1999.
C266	Whitlow et al. "Single-Chain Fv Proteins and Their Fusion Proteins", Methods: A Companion to Methods in Enzymology, 2(2): 97-105, 1991.
C267	Wilson et al. "Hepatocyte-Directed Gene Transfer In Vivo Leads to Transient Improvement of Hypercholesterolemia in Low Density Lipoprotein Receptor-Deficient Rabbits", The Journal of Biological Chemistry, 267(2): 963-967, 1992.
C268	Wilson et al. "Retrovirus-Mediated Transduction of Adult Hepatocytes", Proc. Natl. Acad. Sci. USA, 85: 3014-3018, 1988.
C269	Wolff et al. "Direct Gene Transfer Into Mouse Muscle In Vivo", Science, 247: 1465-1468, 1990.
C270	Wondisford et al. "Cloning of the Human Thyrotropin & Subunit Gene and Transient Expression of Biologically Active Human Thyrotropin After Gene Transfection", Molecular Endocrinology, 2: 32-39, 1988.
C271	Wu et al. "Receptor-Mediated Gene Delivery and Expression In Vivo", The Journal of Biological Chemistry, 263(29): 14621-14624, 1988.
C272	Yin et al. "AC133, A Novel Marker for Human Hematopoietic Stem and Progenitor Cells", Blood, 90(12): 5002-5012, 1997.
C273	Zocchi et al. "Ligand-Induced Internalization of CD38 Results in Intracellular Ca2+ Moblization: Role of NAD+ Transport Across Cell Membranes", FASEB J., 13(2): 273-283, 1999. Abstract.

^{*} By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A9-A140 and the U.S. Published Applications A141-A148 are not submitted.

Examiner Signature	•	Date Considered	
-----------------------	---	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 2189788v.1